Introduction
Tirzepatide is a synthetic dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. As the first member of the ‘twincretin’ class of research peptides, Tirzepatide offers a unique pharmacological profile that has generated significant interest in metabolic, cardiovascular, and adipose tissue biology research. Browse our full GLP-1 research peptides collection or read our GLP-1 Receptor Agonists overview.
For research and laboratory use only. Not intended for human or veterinary administration.
Molecular Structure
Tirzepatide is a 39-amino acid peptide based on the native GIP sequence, with modifications to enable dual receptor activity and extended half-life:
- GIP-based backbone: The peptide sequence is derived from native GIP(1-39), providing primary GIP receptor affinity.
- GLP-1 receptor activity: Specific amino acid substitutions confer potent GLP-1 receptor agonism alongside GIP receptor activity.
- C20 fatty diacid chain: Attached via a linker to enable albumin binding, extending the half-life to approximately 5 days.
- Aib substitutions: Multiple alpha-aminoisobutyric acid substitutions confer DPP-4 resistance.
Dual Receptor Pharmacology
GIP Receptor (GIPR)
The GIP receptor is a class B GPCR expressed in pancreatic beta and alpha cells, adipose tissue, bone, and the central nervous system. GIP receptor activation promotes:
- Glucose-dependent insulin secretion (synergistic with GLP-1R activation)
- Glucagon secretion at low glucose concentrations (unlike GLP-1)
- Lipid uptake and storage in adipose tissue
- Bone formation and reduced resorption
GLP-1 Receptor (GLP-1R)
As described in the GLP-1 research overview, GLP-1R activation promotes insulin secretion, glucagon suppression, gastric emptying delay, and hypothalamic appetite suppression.
Synergistic ‘Twincretin’ Effects
Research suggests that simultaneous activation of both GIPR and GLP-1R produces effects greater than either agonist alone. Proposed mechanisms include:
- Complementary cAMP signalling in beta cells leading to enhanced insulin secretion
- GIPR-mediated sensitisation of adipose tissue to GLP-1R-driven lipolysis
- Central nervous system co-activation producing additive appetite suppression
- Differential effects on glucagon that may improve postprandial glucose control
Metabolic Research Applications
- Obesity models: Superior body weight reduction compared to selective GLP-1 agonists in preclinical dose-response studies.
- Glycaemic control: Enhanced insulin secretion and improved beta-cell function in type 2 diabetes models.
- Adipose tissue biology: Investigation of GIPR-mediated effects on adipocyte function, lipid metabolism, and adipokine secretion.
- NASH/NAFLD: Hepatic steatosis and inflammation reduction in diet-induced liver disease models.
- Bone metabolism: GIPR expression in osteoblasts and osteoclasts makes Tirzepatide of interest in bone biology research.
Cardiovascular Research
Emerging preclinical research has investigated Tirzepatide’s effects on:
- Atherosclerosis progression in hyperlipidaemic models
- Cardiac function and myocardial energy metabolism
- Blood pressure and vascular inflammation markers
- Heart failure models — particularly in the context of obesity-related cardiomyopathy
Related Compounds
Researchers may also wish to explore: Semaglutide (selective GLP-1 agonist), Retatrutide (triple GLP-1/GIP/glucagon agonist), and Cagrilintide (amylin analogue).
Available Concentrations for Research
Vanta Labs supplies Tirzepatide across a wide concentration range to support dose-response, chronic dosing, and comparative studies: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 90 mg, 100 mg, and 120 mg.
Storage and Handling
Store lyophilised Tirzepatide at −20°C, protected from light and moisture. Reconstitute with bacteriostatic water. Once reconstituted, store at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles and agitation.
All products supplied by Vanta Labs are intended strictly for laboratory and research purposes.